Cardiovascular Systems (CSII) Tops Q2 EPS by 3c, Offers Q3 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Leerink Partners Cut Price Target on Cardiovascular Systems (CSII) Following Disappointing 2Q and 3Q Guidance
January 22, 2016 9:22 AM ESTLeerink Partners maintained a Market Perform rating on Cardiovascular Systems (NASDAQ: CSII), and cut the price target to $13.00 (from $17.00), following the company's 2Q earnings report. For F2Q16, CSII reported sales of $41.4M, ~$2M below consensus. Also, management guided F3Q16 revenues well below consensus, yet again, at $40.5M-$42.0M vs. the Street at $46.1M. The guidance indicated what appears to be a more protracted impact than originally expected from the ongoing... More
Needham & Company Downgrades Cardiovascular Systems (CSII) to Underperform
January 22, 2016 7:34 AM ESTNeedham & Company downgraded Cardiovascular Systems (NASDAQ: CSII) from Buy to Underperform, saying positive revenue growth may be a year away.
Analyst Mike Matson commented, "CSII's F2Q16 revenue missed and EPS beat consensus and management guided below consensus for F2Q16. We are... More
